Trial · NCT06028438
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12 | Group 1: Certolizumab and Placebo | -1.86 | 95% Confidence Interval -2.55 to -1.17 | Score on a Scale | |
| Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12 | Group 2: Certolizumab and Nipocalimab | -1.92 | 95% Confidence Interval -2.59 to -1.25 | Score on a Scale | |
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) Response 20 at Week 12 | Group 1: Certolizumab and Placebo | 63.4 | Percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) Response 20 at Week 12 | Group 2: Certolizumab and Nipocalimab | 62.9 | Percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 12 | Group 1: Certolizumab and Placebo | 31.71 | Percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 12 | Group 2: Certolizumab and Nipocalimab | 40.32 | Percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 70 Response at Week 12 | Group 1: Certolizumab and Placebo | 12.20 | Percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 70 Response at Week 12 | Group 2: Certolizumab and Nipocalimab | 14.52 | Percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 90 Response at Week 12 | Group 1: Certolizumab and Placebo | 2.44 | Percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 90 Response at Week 12 | Group 2: Certolizumab and Nipocalimab | 3.23 | Percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Remission at Week 12 | Group 1: Certolizumab and Placebo | 14.63 | Percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Remission at Week 12 | Group 2: Certolizumab and Nipocalimab | 25.81 | Percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Low Disease Activity (LDA) at Week 12 | Group 1: Certolizumab and Placebo | 26.83 | Percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Low Disease Activity (LDA) at Week 12 | Group 2: Certolizumab and Nipocalimab | 43.55 | Percentage of participants | ||
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12 | Group 1: Certolizumab and Placebo | -0.33 | 95% Confidence Interval -0.62 to -0.04 | Score on a scale | |
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12 | Group 2: Certolizumab and Nipocalimab | -0.30 | 95% Confidence Interval -0.58 to -0.02 | Score on a scale | |
| Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Week 12 | Group 1: Certolizumab and Placebo | -22.51 | 95% Confidence Interval -29.23 to -15.78 | Score on a scale | |
| Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Week 12 | Group 2: Certolizumab and Nipocalimab | -21.36 | 95% Confidence Interval -27.89 to -14.83 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06028438/results